Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human LPAR2 Stable Cell Line

    [CAT#: S01YF-0923-PY98]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    GPCR Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Protein
    LPAR2
    Target Family
    Lysophospholipid Family
    Target Protein Species
    Human
    Host Cell Type
    AGS;CHO-K1;HEK293
    Target Classification
    GPCR Cell Lines
    Target Research Area
    Cancer Research
    Related Diseases
    Secretory Diarrhea;Ovarian Cancer
    Gene ID
    Human: 9170

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    LPAR2, a lysophosphatidic acid receptor, has been implicated in various cancer-related processes. In gastric cancer, LPAR2 has been shown to alter cellular energy metabolism through the LPAR2-Axin2 axis, suggesting a potential therapeutic target for this malignancy. Additionally, LPAR2 has been associated with the progression of gastric cancer through the β-catenin signaling pathway. In the context of hepatoma, berberine has been identified as a potential preventive agent, working partially through antagonizing the ATX-LPA-LPAR2-p38-leptin axis. Furthermore, LPAR2 has been linked to the prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human LPAR2 Stable Cell Line (S01YF-0923-PY98). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Timothy (Verified Customer)

    How does LPAR2 influence renal cancer progression? Mar 27 2021

    chat Patrick Liam (Creative Biolabs Scientific Support)

    LPAR2 has been identified as a critical factor for LPA-promoted renal cancer progression. The actions of LPAR2 in promoting renal cancer are mainly dependent on the MAPK and NF-κB activation mechanisms, which regulate the cytokine network. Mar 27 2021

    chat Laura (Verified Customer)

    What role does LPAR2 play in gastric cancer initiation and progression? Feb 21 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    The LPA-LPAR2 axis mediates gastric cancer initiation and progression by increasing energy metabolism via oxidative phosphorylation and glycolysis. Targeting the LPAR2 receptor may offer a novel therapeutic approach to treat gastric cancer. Feb 21 2022

    Published Data

    Fig.1 LPAR2 knockdown reduced LPA-induced proliferation.

    AGS (on the left) and NCI-N87 (on the right) cell lines underwent lentiviral transduction with either a control vector or three distinct LPAR2-shRNA constructs. Subsequently, their response to LPA-induced proliferation was assessed through hemocytometry.

    Ref: Ara, Hosne, et al. "Alteration of Cellular Energy Metabolism through LPAR2-Axin2 Axis in Gastric Cancer." Biomolecules 12.12 (2022): 1805.

    Pubmed: 36551233

    DOI: 10.3390/biom12121805

    Research Highlights

    Takai M, et al. "Induction of lysophosphatidic acid (LPA) receptor-mediated signaling regulates ." Advances in biological regulation, 2023.
    In this study, the researchers evaluated the effects of LPA receptors on the motility and survival of colon cancer DLD-1 cells in the presence of hydrogen peroxide (H(2)O(2)). Lysophosphatidic acid (LPA) signaling through LPA receptors (LPA(1)-LPA(6)) was found to regulate various cellular functions such as growth, migration, and differentiation. To obtain H(2)O(2)-treated DLD-1 cells (DLD-H(2)O(2)), the cells were cultured in a medium containing 60 µM H(2)O(2) for two months. LPAR2 and LPAR4 gene expression levels were significantly increased in DLD-H(2)O(2) cells. The motility of DLD-H(2)O(2) cells was lower compared to DLD-1 cells and was suppressed by LPA(2) knockdown but stimulated by LPA(4) knockdown. DLD-H(2)O(2) cells also exhibited a higher survival rate to anticancer drugs, fluorouracil (5-FU), irinotecan (CPT-11), and oxaliplatin (L-OHP), compared to DLD-1 cells. Knockdown of LPA(2) reduced the survival rate to 5-FU in DLD-H(2)O(2) cells, while knockdown of LPA(4) increased the survival rate. In a hypoxic environment, DLD-H(2)O(2) cells cultured at 1% oxygen showed a higher survival rate to 5-FU compared to DLD-1 cells, which correlated with LPAR2 gene expression. These findings suggest that LPA receptor-mediated signaling is important in regulating cellular functions in H(2)O(2)-treated DLD-1 cells, particularly in the tumor microenvironment with high H(2)O(2) levels.
    Pubmed: 37603941   DOI: 10.1016/j.jbior.2023.100978

    Okuda A, et al. "Roles of lysophosphatidic acid (LPA) receptor-2 (LPA(2)) in the regulation of ." International journal of radiation biology, 2023.
    The roles of Lysophosphatidic acid (LPA) receptor-2 (LPA(2)) in cellular responses to X-ray irradiation and hydrogen peroxide (H(2)O(2)) treatment were studied in pancreatic cancer PANC-1 cells. LPAR2 expression levels were analyzed, and the effects of LPA(2) knockdown on cell survival and motility were evaluated. X-ray irradiation increased LPAR2 expression and decreased cell motility in PANC-1 cells, with enhanced effects in LPA(2) knockdown cells. GRI-977143 (LPA(2) agonist) increased cell survival to X-ray irradiation and CDDP treatment in H(2)O(2) treated cells, while LPA(2) knockdown had the opposite effect. These findings demonstrate the crucial role of LPA(2)-mediated signaling in the regulation of cellular functions in PANC-1 cells following exposure to X-ray irradiation and H(2)O(2).
    Pubmed: 37523658   DOI: 10.1080/09553002.2023.2241890

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare